Pregnant women with myasthenia gravis (MG) are particularly susceptible to severe disease-related complications, usually caused by generalized muscle weakness, which can put the mother and child at risk, according to a recent review study. Newborns should also be monitored for symptoms of transient neonatal MG, a form of…
News
A thymectomy, or surgical removal of the thymus gland, was effective for children and adolescents with myasthenia gravis (MG), as indicated by lower medication use and healthcare utilization after surgery, a study reports. Demographic characteristics like age, sex, ethnicity, insurance payer type, residential region, and the surgical approach…
Having a thymoma, or a tumor in the thymus gland, can make a severe complication of myasthenia gravis (MG) — known as a myasthenic crisis — more likely, a Turkish study suggests. “We found that thymoma increased the risk of developing a myasthenic crisis, and also increased the risk of…
People with myasthenia gravis (MG) experience a lower health-related quality-of-life impact, face a higher medical burden, and require more assistance from caregivers compared with the general population, according to data pulled from two international studies. MG patients also were more likely to take sick leave from work and to…
A new therapy that combines plasmapheresis, or plasma exchange, with the removal of certain immune cells from a person’s blood was seen to result in better outcomes among people with severe myasthenia gravis (MG) than were…
The home infusion company KabaFusion has announced that UCB has tapped it as a limited U.S. distribution partner for Rystiggo (rozanolixizumab-noli), the first therapy approved for adults with the two most common subtypes of generalized myasthenia gravis (gMG). Following its June approval by the U.S. Food…
The approval of Soliris (eculizumab) in the European Union now extends to children and adolescents, ages 6 to 17, with generalized myasthenia gravis (gMG). The European Commission decision covers Soliris’ use in children who have refractory disease, meaning they have failed to respond to standard treatments, and are…
Most people with childhood-onset myasthenia gravis (CMG) experience milder clinical symptoms and a better prognosis than those with adult forms of the disease, according to a recent study in China. For most CMG patients, their disease could be safely controlled with prednisone and other immunosuppressive agents. Researchers also found…
The targeted generalized myasthenia gravis (gMG) treatment Rystiggo (rozanolixizumab-noli) is now commercially available by prescription in the U.S. for eligible adults with gMG, including individuals with antibodies against either the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK), according to its developer. In late June, the therapy from…
On June 27, Rystiggo became the first generalized myasthenia gravis (gMG) treatment to be approved by the U.S. Food and Drug Administration (FDA) for adults with antibodies against either the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) proteins. While other treatments have been cleared for patients with anti-AChR…
Recent Posts
- Zilbrysq safe, effective in real world for treating generalized MG: Study
- The 3 to 5 minutes that act as music therapy for my brother with MG
- Doctors say MG doesn’t cause pain, but my body suggests otherwise
- Taking Vyvgart before thymectomy may help improve surgery outcomes
- Finding ways to reduce suffering, even while living with chronic pain